Published at www.nejm.org March 30, 2008 (10.1056/NEJMoa0800742)
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
John J.P. Kastelein, M.D., Ph.D., Fatima Akdim, M.D., Erik S.G. Stroes, M.D., Ph.D., Aeilko H. Zwinderman, Ph.D., Michiel L. Bots, M.D., Ph.D., Anton F.H. Stalenhoef, M.D., Ph.D., F.R.C.P., Frank L.J. Visseren, M.D., Ph.D., Eric J.G. Sijbrands, M.D., Ph.D., Mieke D. Trip, M.D., Ph.D., Evan A. Stein, M.D., Ph.D., Daniel Gaudet, M.D., Ph.D., Raphael Duivenvoorden, M.D., Enrico P. Veltri, M.D., A. David Marais, M.D., Ph.D., Eric de Groot, M.D., Ph.D., for the ENHANCE Investigators
Background Ezetimibe, a cholesterol-absorption inhibitor, reduceslevels of low-density lipoprotein (LDL) cholesterol when addedto statin treatment. However, the effect of ezetimibe on theprogression of atherosclerosis remains unknown.
Methods We conducted a double-blind, randomized, 24-month trialcomparing the effects of daily therapy with 80 mg of simvastatineither with placebo or with 10 mg of ezetimibe in 720 patientswith familial hypercholesterolemia. Patients underwent B-modeultrasonography to assess the intima–media thickness ofthe walls of the carotid and femoral arteries. The primary outcomemeasure was the change in the mean carotid-artery intima–mediathickness, which was defined as the average of the means ofthe far-wall intima–media thickness of the right and leftcommon carotid arteries, carotid bulbs, and internal carotidarteries.
Results The primary outcome, the mean (±SE) change inthe carotid-artery intima–media thickness, was 0.0058±0.0037mm in the simvastatin-only group and 0.0111±0.0038 mmin the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29).Secondary outcomes (consisting of other variables regardingthe intima–media thickness of the carotid and femoralarteries) did not differ significantly between the two groups.At the end of the study, the mean (±SD) LDL cholesterollevel was 192.7±60.3 mg per deciliter (4.98±1.56mmol per liter) in the simvastatin group and 141.3±52.6mg per deciliter (3.65±1.36 mmol per liter) in the combined-therapygroup (a between-group difference of 16.5%, P<0.01). Thedifferences between the two groups in reductions in levels oftriglycerides and C-reactive protein were 6.6% and 25.7%, respectively,with greater reductions in the combined-therapy group (P<0.01for both comparisons). Side-effect and safety profiles weresimilar in the two groups.
Conclusions In patients with familial hypercholesterolemia,combined therapy with ezetimibe and simvastatin did not resultin a significant difference in changes in intima–mediathickness, as compared with simvastatin alone, despite decreasesin levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.govnumber, NCT00552097
[ClinicalTrials.gov]
.)
Source Information
From the Academic Medical Center, Amsterdam (J.J.P.K., F.A., E.S.G.S., A.H.Z., M.D.T., R.D., E.G.); the University Medical Center, Utrecht (M.L.B., F.L.J.V.); Radboud University Nijmegen Medical Center, Nijmegen (A.F.H.S.); and Erasmus Medical Center, Rotterdam (E.J.G.S.) — all in the Netherlands; the Metabolic and Atherosclerosis Research Center, Cincinnati (E.A.S.); the Quebec Heart Institute, Hôpital Laval Research Centre, Quebec, QC, Canada (D.G.); Schering-Plough Research Institute, Kenilworth, NJ (E.P.V.); and Cape Heart Center, Cape Town, South Africa (A.D.M.). This article (10.1056/NEJMoa0800742) was published at www.nejm.org on March 30, 2008. It will appear in the April 3 issue of the Journal.
Address reprint requests to Dr. Kastelein at the Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, P.O. Box 22660, 1100 DD Amsterdam, the Netherlands, or at j.j.kastelein{at}amc.uva.nl.
Finn, A. V., Kolodgie, F. D., Virmani, R.
(2010). Correlation Between Carotid Intimal/Medial Thickness and Atherosclerosis: A Point of View From Pathology. Arterioscler. Thromb. Vasc. Bio.
30: 177-181
[Abstract][Full Text]
Bass, A., Hinderliter, A. L, Lee, C. R
(2009). The Impact of Ezetimibe on Endothelial Function and Other Markers of Cardiovascular Risk. The Annals of Pharmacotherapy
43: 2021-2030
[Abstract][Full Text]
Blumenthal, R. S., Michos, E. D.
(2009). The HALTS Trial -- Halting Atherosclerosis or Halted Too Early?. NEJM
361: 2178-2180
[Full Text]
Kastelein, J. J.P., Bots, M. L.
(2009). Statin Therapy with Ezetimibe or Niacin in High-Risk Patients. NEJM
361: 2180-2183
[Full Text]
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M., Weissman, N. J., Turco, M.
(2009). Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness. NEJM
361: 2113-2122
[Abstract][Full Text]
Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., Moher, D.
(2009). Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia. ANN INTERN MED
151: 622-630
[Abstract][Full Text]
Greenberg, M. E., Smith, J. D., Sehayek, E.
(2009). Moderately Decreased Cholesterol Absorption Rates Are Associated With a Large Atheroprotective Effect. Arterioscler. Thromb. Vasc. Bio.
29: 1745-1750
[Abstract][Full Text]
Nilsson, P. M.
(2009). Hypertension and Diabetes: Should We Treat Early Surrogates?: What are the cons?. Diabetes Care
32: S290-S293
[Full Text]
Eldor, R., Raz, I.
(2009). American Diabetes Association Indications for Statins in Diabetes: Is there evidence?. Diabetes Care
32: S384-S391
[Full Text]
Macaulay, T. E., Cook, A. M., Fink, J. L. III, Rapp, R. P., Vincent, W. R. III
(2009). Pharmacists' role in facilitating evidence-based prescribing for unlabeled use of medications. Am J Health Syst Pharm
66: 1735-1739
[Full Text]
Thompson, G.
(2009). History of the cholesterol hypothesis in Britain. QJM
102: 750-751
[Full Text]
Puntmann, V O
(2009). How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgrad. Med. J.
85: 538-545
[Abstract][Full Text]
Masia, M., Bernal, E., Padilla, S., Garcia, N., Escribano, J. C., Martinez, E., Gutierrez, F.
(2009). A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk. J Antimicrob Chemother
64: 589-598
[Abstract][Full Text]
Hirsch, L. J.
(2009). Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications: The Tort Bar and Editorial Oversight of Medical Journals. Mayo Clin Proc.
84: 811-821
[Full Text]
Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., Moher, D.
(2009). Systematic Review: Comparative Effectiveness and Harms of Combinations of Lipid-Modifying Agents and High-Dose Statin Monotherapy. ANN INTERN MED
0: 0000605-200911030-00144v1-E-144
[Abstract][Full Text]
(2009). {blacktriangledown}Ezetimibe - an update. DTB
47: 91-95
[Abstract][Full Text]
Gould, A L., Koglin, J., Bain, R. P, Pinto, C.-A., Mitchel, Y. B, Pasternak, R. C, Sapre, A.
(2009). Effects of sources of variability on sample sizes required for RCTs, applied to trials of lipid-altering therapies on carotid artery intima-media thickness. Clin Trials
6: 305-319
[Abstract]
Carr, T. P., Krogstrand, K. L. S., Schlegel, V. L., Fernandez, M. L.
(2009). Stearate-Enriched Plant Sterol Esters Lower Serum LDL Cholesterol Concentration in Normo- and Hypercholesterolemic Adults. J. Nutr.
139: 1445-1450
[Abstract][Full Text]
Hirsch, R.
(2009). Changing the Diabetes Treatment Paradigm. Arch Intern Med
169: 1246-1246
[Full Text]
Meaney, A., Ceballos, G., Asbun, J., Solache, G., Mendoza, E., Vela, A., Meaney, E.
(2009). The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) Study. J Clin Pharmacol
49: 838-847
[Abstract][Full Text]
Allen, L. A., Hernandez, A. F., O'Connor, C. M., Felker, G. M.
(2009). End points for clinical trials in acute heart failure syndromes.. J Am Coll Cardiol
53: 2248-2258
[Abstract][Full Text]
Goumas, G. S.
(2009). LDL-Cholesterol is the King. ANGIOLOGY
60: 387-388
Grimes, D. S.
(2009). History of the cholesterol hypothesis in Britain. QJM
102: 436-438
[Full Text]
Meijer, P., Oyen, W. J.G., Dekker, D., van den Broek, P. H.H., Wouters, C. W., Boerman, O. C., Scheffer, G. J., Smits, P., Rongen, G. A.
(2009). Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo: A New Perspective on Cardiovascular Protection. Arterioscler. Thromb. Vasc. Bio.
29: 963-968
[Abstract][Full Text]
Gellad, W. F., Detsky, A. S., Choudhry, N. K.
(2009). Implications of recent clinical trials on pay-for-performance. Am J Health Syst Pharm
66: 864-867
[Full Text]
Duivenvoorden, R., de Groot, E., Elsen, B.M., Lameris, J.S., van der Geest, R.J., Stroes, E.S., Kastelein, J.J.P., Nederveen, A.J.
(2009). In Vivo Quantification of Carotid Artery Wall Dimensions: 3.0-Tesla MRI Versus B-Mode Ultrasound Imaging. Circ Cardiovasc Imaging
2: 235-242
[Abstract][Full Text]
Sanz, J., Moreno, P. R., Fuster, V.
(2009). The Year in Atherothrombosis. J Am Coll Cardiol
53: 1326-1337
[Full Text]
Escarcega, R., Garcia-Carrasco, M, Jara, L., Cervera, R
(2009). Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality. Lupus
18: 383-386
van Himbergen, T. M., Matthan, N. R., Resteghini, N. A., Otokozawa, S., Ai, M., Stein, E. A., Jones, P. H., Schaefer, E. J.
(2009). Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J. Lipid Res.
50: 730-739
[Abstract][Full Text]
Chowdhury, T. A, Hitman, G. A
(2009). NICE guidance for identification and treatment of familial hypercholesterolaemia: Commentary 1. Heart
95: 587-589
[Full Text]
Minhas, R, Humphries, S E, Qureshi, N, Neil, H A W, on behalf of the NICE Guideline Development Group,
(2009). Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart
95: 584-587
[Full Text]
Stein, E. A.
(2009). Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. Mayo Clin Proc.
84: 307-309
[Full Text]
Al Badarin, F. J., Kullo, I. J., Kopecky, S. L., Thomas, R. J.
(2009). Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?. Mayo Clin Proc.
84: 353-361
[Abstract][Full Text]
Meuwese, M. C., de Groot, E., Duivenvoorden, R., Trip, M. D., Ose, L., Maritz, F. J., Basart, D. C. G., Kastelein, J. J. P., Habib, R., Davidson, M. H., Zwinderman, A. H., Schwocho, L. R., Stein, E. A., for the CAPTIVATE Investigators,
(2009). ACAT Inhibition and Progression of Carotid Atherosclerosis in Patients With Familial Hypercholesterolemia: The CAPTIVATE Randomized Trial. JAMA
301: 1131-1139
[Abstract][Full Text]
Adolphe, A., Cook, L. S., Huang, X.
(2009). A Cross-sectional Study of Intima-Media Thickness, Ethnicity, Metabolic Syndrome, and Cardiovascular Risk in 2268 Study Participants. Mayo Clin Proc.
84: 221-228
[Abstract][Full Text]
Silbernagel, G., Fauler, G., Renner, W., Landl, E. M., Hoffmann, M. M., Winkelmann, B. R., Boehm, B. O., Marz, W.
(2009). The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease. J. Lipid Res.
50: 334-341
[Abstract][Full Text]
Goumas, G. S.
(2009). Is There Evidence-based Hypolipidemic Treatment With Clinical Benefit Beyond Statins?. ANGIOLOGY
60: 93-98
[Abstract]
Mascitelli, L., Ravnskov, U., Pezzetta, F., Goldstein, M. R.
(2009). After the Failure of ENHANCEd Cholesterol Lowering in Familial Hypercholesterolemia, SEAS of Problems with Ezetimibe. ANGIOLOGY
60: 127-128
Liu, P.-Y., Liu, Y.-W., Lin, L.-J., Chen, J.-H., Liao, J. K.
(2009). Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation. Circulation
119: 131-138
[Abstract][Full Text]
Dentzer, S.
(2009). Communicating Medical News -- Pitfalls of Health Care Journalism. NEJM
360: 1-3
[Full Text]
Stebbing, J., Asghar, A. K., Holmes, P., Bower, M., Isenman, H. L., Nelson, M.
(2009). Use of ezetimibe during HIV infection. J Antimicrob Chemother
63: 218-220
[Full Text]
Whayne, T. F. Jr
(2009). Is There a Problem With Ezetimibe or Just ENHANCEd Hype?. ANGIOLOGY
59: 661-663
Stein, E. A.
(2008). Additional Lipid Lowering Trials Using Surrogate Measurements of Atherosclerosis by Carotid Intima-Media Thickness: More Clarity or Confusion?. J Am Coll Cardiol
52: 2206-2209
[Full Text]
Fleg, J. L., Mete, M., Howard, B. V., Umans, J. G., Roman, M. J., Ratner, R. E., Silverman, A., Galloway, J. M., Henderson, J. A., Weir, M. R., Wilson, C., Stylianou, M., Howard, Wm. J.
(2008). Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) Trial. J Am Coll Cardiol
52: 2198-2205
[Abstract][Full Text]
Kimberlin, C. L., Winterstein, A. G.
(2008). Validity and reliability of measurement instruments used in research. Am J Health Syst Pharm
65: 2276-2284
[Abstract][Full Text]
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., Eckel, R. H.
(2008). The Metabolic Syndrome. Endocr. Rev.
29: 777-822
[Abstract][Full Text]
Versmissen, J., Oosterveer, D. M, Yazdanpanah, M., Defesche, J. C, Basart, D. C G, Liem, A. H, Heeringa, J., Witteman, J. C, Lansberg, P. J, Kastelein, J. J P, Sijbrands, E. J G
(2008). Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ
337: a2423-a2423
[Abstract][Full Text]
DAVIDSON, M. H.
(2008). IN REPLY. Cleveland Clinic Journal of Medicine
75: 767-767
[Full Text]
Pasquali, S. K., Li, J. S.
(2008). Prevention of Future Cardiovascular Disease in High-Risk Pediatric Patients: A Role for Lipid Lowering Therapy?. Circ Cardiovasc Qual Outcomes
1: 131-133
[Full Text]
Neil, A., Cooper, J., Betteridge, J., Capps, N., McDowell, I., Durrington, P., Seed, M., Humphries, S. E., on behalf of the Simon Broome Familial Hyperlipida,
(2008). Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J
29: 2625-2633
[Abstract][Full Text]
Spence, J. D.
(2008). Is Carotid Intima-Media Thickness a Reliable Clinical Predictor?. Mayo Clin Proc.
83: 1299-1300
[Full Text]
Bhattacharyya, O. K. MD PhD, Shah, B. R. MD PhD, Booth, G. L. MD MSc
(2008). Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CMAJ
179: 920-926
[Full Text]
MANDELL, B. F.
(2008). When A Quick Sound Bite Won't Do. Cleveland Clinic Journal of Medicine
75: 686-686
[Full Text]
Steiner, M. J., Brown, W. D., Liles, E.
(2008). An Assessment of the New Lipid Screening Guidelines. Pediatrics
122: 904-905
[Full Text]
Taylor, A. J., Nissen, S. E.
(2008). Preliminary Observations From Preliminary Trial Results: Have We Finally Had Enough?. Circ Cardiovasc Qual Outcomes
1: 54-57
[Full Text]
O'Keefe, J. H., Bybee, K. A., Lavie, C. J.
(2008). Intensive Lipid Intervention in the Post-ENHANCE Era. Mayo Clin Proc.
83: 867-869
[Full Text]
Toutouzas, P., Richter, D.
(2008). Carotid Intima--Media Thickness (cIMT): A Useful Clinic Tool or Research Luxury? Another View of the ENHANCE Trial. ANGIOLOGY
59: 77S-79S
[Abstract]
Andrikopoulos, G. K., Tzeis, S.
(2008). Modification of Cardiometabolic Risk Through Cannabinoid Type-1 Receptor Antagonism. ANGIOLOGY
59: 44S-48S
[Abstract]
Steinberg, D., Eichhorn, E. J., Connor, W. E., Diamond, G. A., Kaul, S., Blake, J. A., Davis, H. R. Jr., Murgolo, N. J., Graziano, M. P., Kaye, T., Akdim, F., de Groot, E., Kastelein, J. J.P., Brown, B. G.
(2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia.. NEJM
359: 529-530
[Full Text]
Kinlay, S.
(2008). Vascular form and function: two mechanisms for cardiovascular prevention. Eur Heart J
29: 1711-1713
[Full Text]
DAVIDSON, M. H.
(2008). Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleveland Clinic Journal of Medicine
75: 479-496
[Full Text]
TAYLOR, A. J.
(2008). Given the ENHANCE trial results, ezetimibe is still unproven. Cleveland Clinic Journal of Medicine
75: 497-506
[Full Text]
Resnic, F. S., Desai, A.
(2008). Highlights from the 57th Annual Scientific Session of the American College of Cardiology. J. Thorac. Cardiovasc. Surg.
136: 244-247
[Full Text]
Ridker, P. M
(2008). The Time for Cardiovascular Inflammation Reduction Trials Has Arrived: How Low to Go for hsCRP?. Arterioscler. Thromb. Vasc. Bio.
28: 1222-1224
[Full Text]
Triplitt, C., Alvarez, C. A.
(2008). Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectr.
21: 177-189
[Abstract][Full Text]
Becker, D. J., Gordon, R. Y., Morris, P. B., Yorko, J., Gordon, Y. J., Li, M., Iqbal, N.
(2008). Simvastatin vs Therapeutic Lifestyle Changes and Supplements: Randomized Primary Prevention Trial. Mayo Clin Proc.
83: 758-764
[Abstract][Full Text]
Greenland, P., Lloyd-Jones, D.
(2008). The ENHANCE Study and Marketing Ezetimibe--Reply. JAMA
299: 2747-2748
[Full Text]
Gandhi, G. Y., Murad, M. H., Fujiyoshi, A., Mullan, R. J., Flynn, D. N., Elamin, M. B., Swiglo, B. A., Isley, W. L., Guyatt, G. H., Montori, V. M.
(2008). Patient-Important Outcomes in Registered Diabetes Trials. JAMA
299: 2543-2549
[Abstract][Full Text]
Stein, E. A.
(2008). After ENHANCE: Is More LDL Cholesterol Lowering Even Better?. Clin. Chem.
54: 940-942
[Full Text]
Repas, T. B.
(2008). Think Beyond the Numbers, Don't Forget the Patient. JAOA: Journal of the American Osteopathic Association
108: ii-S4
[Full Text]
Jackevicius, C. A., Tu, J. V., Ross, J. S., Ko, D. T., Krumholz, H. M.
(2008). Use of Ezetimibe in the United States and Canada. NEJM
358: 1819-1828
[Abstract][Full Text]
Brown, B. G., Taylor, A. J.
(2008). Does ENHANCE Diminish Confidence in Lowering LDL or in Ezetimibe?. NEJM
358: 1504-1507
[Full Text]
Drazen, J. M., Jarcho, J. A., Morrissey, S., Curfman, G. D.
(2008). Cholesterol Lowering and Ezetimibe. NEJM
358: 1507-1508
[Full Text]
(2008). Does Ezetimibe ENHANCE the Benefits of Statins?. Journal Watch Cardiology
2008: 1-1
[Full Text]
